Time on therapy and concomitant medication use of mepolizumab in Canada: A retrospective cohort study
- 1Evidence Based Medical Educator, Toronto, Canada
- 2AstraZeneca, Mississauga, Canada
- 3Department of Medicine, University of Montreal, Quebec, Canada
- 4University of Toronto, Toronto, Canada
- 5Department of Health Research Methods, Evidence and Impact (HEI), McMaster University, Hamilton, Canada
- Stephen Noorduyn, Medical Evidence Team, Scientific Affairs, AstraZeneca Canada, 1004 Middlegate Road, Mississauga, ON, L4Y 1M4 Canada. E-Mail: Stephen.noorduyn{at}astrazeneca.com
Footnotes
This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.
Conflict of Interest: SG Noorduyn reports employment with AstraZeneca Canada both during the conduct of the study and outside the submitted work.
This is a PDF-only article. Please click on the PDF link above to read it.
- Received October 23, 2020.
- Accepted January 31, 2021.
- ©The authors 2021
This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org